Perspectives for an integrated biomarker approach to drug discovery and development

Biomarkers for Psychiatric Disorders

Volumn , Issue , 2009, Pages 355-403

  Antonijevic, Irina ^a   Artymyshyn, Roman ^b   Forray, Carlos ^b   Rabacchi, Sylvia ^b   Smith, Kelli ^b   Swanson, Chad ^b   Tamm, Joseph ^b   Mazin, Wiktor ^b   Gerald, Christophe ^b  

^a LUNDBECK RESEARCH USA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876148837     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-79251-4_15     Document Type: Chapter

References (247)

1. A Research Agenda for DSM-V™ Washington, D.C. American Psychiatric Association 2002)
2. Abercrombie, E. D., Jacobs, B. L.: Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats I Acutely presented stressful and nonstressful stimuli. J Neurosci 7, 2837-2843 (1987)
3. Akaoka, H., Aston-Jones, G.: Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input. J Neurosci 11, 3830-3839 (1991)
4. Alfonso, J., Pollevick, G. D., van der Hart, M. G., Flugge, G., Fuchs, E., Frasch, A. C.: Identification of genes regulated by chronic psychosocial stress and antidepressant treatment in the hippocampus. Eur J Neurosci 19, 659-666 (2004)
5. Altar, C. A., Laeng, P., Jurata, L. W., Brockman, J. A., Lemire, A., Bullard, J., Bukhman, Y. V., Young, T. A., Charles, V., Palfreyman, M. G.: Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 24, 2667-2677 (2004)
6. Andersen, C. L., Jensen, J. L., Orntoft, T. F.: Normalization of real-Time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64, 5245-5250 (2004)
7. Armitage, R., Hoffmann, R. F., Rush, A. J.: Biological rhythm disturbance in depression: Temporal coherence of ultradian sleep EEG rhythms. Psychol. Med. 29, 1435-1448 (1999)
8. Armitage, R., Hoffmann, R., Trivedi, M., Rush, A. J.: Slow-wave activity in NREM sleep: Sex and age effects in depressed outpatients and healthy controls. Psychiatry Res. 95, 201-213 (2000)
9. Armitage, R., Emslie, G. J., Hoffmann, R. F., Rintelmann, J., Rush, A. J.: Delta sleep EEG in depressed adolescent females and healthy controls. J. Affect. Disord. 63, 139-148 (2001)
10. Armitage, R., Hoffmann, R., Emslie, G., Rintelmann, J., Robert, J.: Sleep microarchitecture in childhood and adolescent depression: Temporal coherence. Clin. EEG. Neurosci. 37, 1-9 (2006)
11. Atz, M., Walsh, D., Cartagena, P., Li, J., Evans, S., Choudary, P., Overman, K., Stein, R., Tomita, H., Potkin, S., Myers, R., Watson, S. J., Jones, E. G., Akil, H., Bunney, W. E., Jr., Vawter, M. P.: Methodological considerations for gene expression profiling of human brain. J. Neurosci. Methods 163, 295-309 (2007)
12. Avissar, S., Matuzany-Ruban, A., Tzukert, K., Schreiber, G.: Beta-Arrestin-1 levels: Reduced in leukocytes of patients with depression and elevated by antidepressants in rat brain. Am. J. Psychiatry 161, 2066-2072 (2004)
13. Basta-Kaim, A., Budziszewska, B., Jaworska-Feil, L., Tetich, M., Kubera, M., Leskiewicz, M., Lason, W.: Inhibitory effect of imipramine on the human corticotropin-releasing-hormone gene promoter activity operates through a PI3-K/AKT mediated pathway. Neuropharmacology 49, 156-164 (2005)
14. Bellon, A.: New genes associated with schizophrenia in neurite formation: A review of cell culture experiments. Mol Psychiatry 12, 620-629 (2007)
15. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001)
16. Birthelmer, A., Ehret, A., Riegert, C., Rothmaier, A. K., Leemhuis, J., Jackisch, R.: Modulation of electrically evoked serotonin release in cultured rat raphe neurons. J Neurochem 100, 1613-1625 (2007)
17. Blackwood, D. H., Pickard, B. J., Thomson, P. A., Evans, K. L., Porteous, D. J., Muir, W. J.: Are some genetic risk factors common to schizophrenia, bipolar disorder and depression? Evidence from DISC1, GRIK4 and NRG1. Neurotox. Res 11, 73-83 (2007)
18. Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., Maes, M.: Increased depressive ratings in patients with hepatitis C receiving interferon-Alpha-based immunotherapy are related to interferon-Alpha-induced changes in the serotonergic system. J. Clin. Psychopharmacol. 22, 86-90 (2002)
19. Borsini, F.: Role of the serotonergic system in the forced swimming test. Neurosci Biobehav. Rev 19, 377-395 (1995)
20. Bosotti, R., Locatelli, G., Healy, S., Scacheri, E., Sartori, L., Mercurio, C., Calogero, R., Isacchi, A.: Cross platform microarray analysis for robust identification of differentially expressed genes. BMC Bioinformatics 8 Suppl 1, S5 (2007)
21. Brazeau, D. A.: Combining genome-wide and targeted gene expression profiling in drug discovery: Microarrays and real-Time PCR. Drug Discov. Today. 9, 838-845 (2004)
22. Bremner, J. D., Krystal, J. H., Southwick, S. M., Charney, D. S.: Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse. 23, 28-38 (1996)
23. Brenner, S., Johnson, M., Bridgham, J., Golda, G., Lloyd, D. H., Johnson, D., Luo, S., McCurdy, S., Foy, M., Ewan, M., Roth, R., George, D., Eletr, S., Albrecht, G., Vermaas, E., Williams, S. R., Moon, K., Burcham, T., Pallas, M., DuBridge, R. B., Kirchner, J., Fearon, K., Mao, J., Corcoran, K.: Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat. Biotechnol. 18, 630-634 (2000)
24. Browning, M. D., Dudek, E. M., Rapier, J. L., Leonard, S., Freedman, R.: Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol Psychiatry 34, 529-535 (1993)
25. Budziszewska, B., Jaworska-Feil, L., Tetich, M., Basta-Kaim, A., Kubera, M., Leskiewicz, M., Lason, W.: Regulation of the human corticotropin-releasing- hormone gene promoter activity by antidepressant drugs in Neuro-2A and AtT-20 cells. Neuropsychopharmacology 29, 785-794 (2004)
26. Bundey, R. A., Iredale, P. A., Kendall, D. A.: Corticosteroid modulation of signal transduction in the CATH.a cell line. J Neurochem 68, 362-369 (1997)
27. Bundey, R. A., Kendall, D. A.: Inhibition of receptor-mediated calcium responses by corticotrophin-releasing hormone in the CATH.a cell line. Neuropharmacology 38, 39-47 (1999)
28. Canales, R. D., Luo, Y., Willey, J. C., Austermiller, B., Barbacioru, C. C., Boysen, C., Hunkapiller, K., Jensen, R. V., Knight, C. R., Lee, K. Y., Ma, Y., Maqsodi, B., Papallo, A., Peters, E. H., Poulter, K., Ruppel, P. L., Samaha, R. R., Shi, L., Yang, W., Zhang, L., Goodsaid, F. M.: Evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol. 24, 1115-1122 (2006)
29. Capuron, L., Dantzer, R.: Cytokines and depression: The need for a new paradigm. Brain Behav. Immun. 17 Suppl 1, S119-S124 (2003)
30. Capuron, L., Miller, A. H.: Cytokines and psychopathology: Lessons from interferon-Alpha. Biol. Psychiatry 56, 819-824 (2004)
31. Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., Miller, A. H.: Interferon-Alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol. Psychiatry 54, 906-914 (2003)
32. Capuron, L., Raison, C. L., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Miller, A. H.: Association of exaggerated HPA axis response to the initial injection of interferon-Alpha with development of depression during interferon-Alpha therapy. Am. J. Psychiatry 160, 1342-1345 (2003)
33. Carroll, B. J., Curtis, G. C., Mendels, J.: Neuroendocrine regulation in depression II Discrimination of depressed from nondepressed patients. Arch. Gen. Psychiatry 33, 1051-1058 (1976)
34. Carroll, B. J., Cassidy, F., Naftolowitz, D., Tatham, N. E., Wilson, W. H., Iranmesh, A., Liu, P. Y., Veldhuis, J. D.: Pathophysiology of hypercortisolism in depression. Acta Psychiatrica Scandinavica 115, 90-103 (2007)
35. Cartmell, J., Schoepp, D. D.: Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75, 889-907 (2000)
36. Charmandari, E., Tsigos, C., Chrousos, G.: Endocrinology of the stress response. Annu. Rev Physiol 67, 259-284 (2005)
37. Charney, D. S., Heninger, G. R., Breier, A.: Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry 41, 751-763 (1984)
38. Charney DS, Barlow DH, Botteron K, Cohen JD, Goldman D, Gur RE, Lin K-M, Lopez JF, Meador-Woodruff JH, Moldin SO, Nestler EJ, Watson SJ, Zalcman SJ. Neuroscience Research Agenda to Guide Development of a Pathophysiologically Based Classification System. In: Kupfer DJ, First MB, Regier DA, editors. A Research Agenda for DSM-V ™. Washington, D.C.: American Psychiatric Association, 2002. p. 31-84.
39. Chiou, S. H., Chen, S. J., Peng, C. H., Chang, Y. L., Ku, H. H., Hsu, W. M., Ho, L. L., Lee, C. H.: Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPSinduced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys. Res Commun. 343, 391-400 (2006)
40. Chiou, S. H., Ku, H. H., Tsai, T. H., Lin, H. L., Chen, L. H., Chien, C. S., Ho, L. L., Lee, C. H., Chang, Y. L.: Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Br. J Pharmacol 148, 587-598 (2006)
41. Claes, S. J.: Corticotropin-releasing hormone (CRH) in psychiatry: From stress to psychopathology. Ann Med 36, 50-61 (2004)
42. Crochemore, C., Lu, J., Wu, Y., Liposits, Z., Sousa, N., Holsboer, F., Almeida, O. F.: Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 10, 790-798 (2005)
43. Cryan, J. F., Holmes, A.: The ascent of mouse: Advances in modelling human depression and anxiety. Nat. Rev Drug Discov. 4, 775-790 (2005)
44. Cryan, J. F., Mombereau, C.: In search of a depressed mouse: Utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9, 326-357 (2004)
45. Cryan, J. F., Slattery, D. A.: Animal models of mood disorders: Recent developments. Curr. Opin. Psychiatry 20, 1-7 (2007)
46. Cryan, J. F., Mombereau, C., Vassout, A.: The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav. Rev 29, 571-625 (2005)
47. Cryan, J. F., Valentino, R. J., Lucki, I.: Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav. Rev 29, 547-569 (2005)
48. Czesak, M., Lemonde, S., Peterson, E. A., Rogaeva, A., Albert, P. R.: Cell-specific repressor or enhancer activities of Deaf-1 at a serotonin 1A receptor gene polymorphism. J Neurosci 26, 1864-1871 (2006)
49. David, D. J., Klemenhagen, K. C., Holick, K. A., Saxe, M. D., Mendez, I., Santarelli, L., Craig, D. A., Zhong, H., Swanson, C. J., Hegde, L. G., Ping, X. I., Dong, D., Marzabadi, M. R., Gerald, C. P., Hen, R.: Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy) phenyl]methyl}(4-piperidyl))-4- methylphen yl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J Pharmacol Exp Ther 321, 237-248 (2007)
50. Davidson, R. J., Irwin, W., Anderle, M. J., Kalin, N. H.: The neural substrates of affective processing in depressed patients treated with venlafaxine. Am. J. Psychiatry 160, 64-75 (2003)
51. De Pablo, J. M., Parra, A., Segovia, S., Guillamon, A.: Learned immobility explains the behavior of rats in the forced swimming test. Physiol Behav 46, 229-237 (1989)
52. Detke, M. J., Rickels, M., Lucki, I.: Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology. (Berl) 121, 66-72 (1995)
53. Dettling, M., Buhlmann, P.: Finding predictive gene groups from microarray data. J. Multivariate Analysis 90, 106-131 (2004)
54. Draper, I., Kurshan, P. T., McBride, E., Jackson, F. R., Kopin, A. S.: Locomotor activity is regulated by D2-like receptors in Drosophila: An anatomic and functional analysis. Dev Neurobiol 67, 378-393 (2007)
55. D'Sa, C., Duman, R. S.: Antidepressants and neuroplasticity. Bipolar Disord. 4, 183-194 (2002)
56. Duncan, G. E., Breese, G. R., Criswell, H. E., Johnson, K. B., Schambra, U. B., Mueller, R. A., Caron, M. G., Fremeau, R. T., Jr.: D1 dopamine receptor binding and mRNA levels are not altered after neonatal 6-hydroxydopamine treatment: Evidence against dopamine-mediated induction of D1 dopamine receptors during postnatal development. J Neurochem 61, 1255-1262 (1993)
57. Ehret, A., Birthelmer, A., Rutz, S., Riegert, C., Rothmaier, A. K., Jackisch, R.: Agonist-mediated regulation of presynaptic receptor function during development of rat septal neurons in culture. J Neurochem 102, 1071-1082 (2007)
58. Emanuel, R. L., Girard, D. M., Thull, D. L., Majzoub, J. A.: Second messengers involved in the regulation of corticotropin-releasing hormone mRNA and peptide in cultured rat fetal hypothalamic primary cultures. Endocrinology 126, 3016-3021 (1990)
59. Eriksson, P. S., Perfilieva, E., Bjork-Eriksson, T., Alborn, A. M., Nordborg, C., Peterson, D. A., Gage, F. H.: Neurogenesis in the adult human hippocampus. Nat. Med 4, 1313-1317 (1998)
60. Evans, S. J., Choudary, P. V., Neal, C. R., Li, J. Z., Vawter, M. P., Tomita, H., Lopez, J. F., Thompson, R. C., Meng, F., Stead, J. D., Walsh, D. M., Myers, R. M., Bunney, W. E., Watson, S. J., Jones, E. G., Akil, H.: Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci U S A 101, 15506-15511 (2004)
61. Feezor, R. J., Baker, H. V., Mindrinos, M., Hayden, D., Tannahill, C. L., Brownstein, B. H., Fay, A., MacMillan, S., Laramie, J., Xiao, W., Moldawer, L. L., Cobb, J. P., Laudanski, K., Miller-Graziano, C. L., Maier, R. V., Schoenfeld, D., Davis, R. W., Tompkins, R. G.: Whole blood and leukocyte RNA isolation for gene expression analyses. Physiol Genomics 19, 247-254 (2004)
62. Frank, R., Hargreaves, R.: Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2, 566-580 (2003)
63. Frenois, F., Cador, M., Caille, S., Stinus, L., Le, M. C.: Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16, 1377-1389 (2002)
64. Frodl, T., Meisenzahl, E. M., Zetzsche, T., Hohne, T., Banac, S., Schorr, C., Jager, M., Leinsinger, G., Bottlender, R., Reiser, M., Moller, H. J.: Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J. Clin. Psychiatry 65, 492-499 (2004)
65. Frohna, P. A., Neal-Beliveau, B. S., Joyce, J. N.: Neonatal 6-hydroxydopamine lesions lead to opposing changes in the levels of dopamine receptors and their messenger RNAs. Neuroscience 68, 505-518 (1995)
66. Fu, C. H., Williams, S. C., Cleare, A. J., Brammer, M. J., Walsh, N. D., Kim, J., Andrew, C. M., Pich, E. M., Williams, P. M., Reed, L. J., Mitterschiffthaler, M. T., Suckling, J., Bullmore, E. T.: Attenuation of the neural response to sad faces in major depression by antidepressant treatment: A prospective, event-related functional magnetic resonance imaging study. Arch. Gen. Psychiatry 61, 877-889 (2004)
67. Funada, M., Hara, C., Wada, K.: Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system. Eur J Pharmacol 430, 277-281 (2001)
68. Ganguly, S., Coon, S. L., Klein, D. C.: Control of melatonin synthesis in the mammalian pineal gland: The critical role of serotonin acetylation. Cell Tissue Res 309, 127-137 (2002)
69. Garcia-Sevilla, J. A., Zis, A. P., Hollingsworth, P. J., Greden, J. F., Smith, C. B.: Platelet alpha 2-Adrenergic receptors in major depressive disorder. Binding of tritiated clonidine before and after tricyclic antidepressant drug treatment. Arch. Gen. Psychiatry 38, 1327-1333 (1981)
70. Georges, M., Coppieters, W., Charlier, C.: Polymorphic miRNA-mediated gene regulation: Contribution to phenotypic variation and disease. Curr. Opin. Genet. Dev. 17, 166-176 (2007)
71. Ghaffar, O., Feinstein, A.: The neuropsychiatry of multiple sclerosis: A review of recent developments. Curr. Opin. Psychiatry 20, 278-285 (2007)
72. Gilbertson, M. W., Shenton, M. E., Ciszewski, A., Kasai, K., Lasko, N. B., Orr, S. P., Pitman, R. K.: Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat. Neurosci. 5, 1242-1247 (2002)
73. Gladkevich, A., Kauffman, H. F., Korf, J.: Lymphocytes as a neural probe: Potential for studying psychiatric disorders. Prog. Neuropsychopharmacol. Biol Psychiatry 28, 559-576 (2004)
74. Glantz, L. A., Lewis, D. A.: Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch. Gen. Psychiatry 54, 943-952 (1997)
75. Glavin, G. B.: Selective noradrenaline depletion markedly alters stress responses in rats. Life Sci 37, 461-465 (1985)
76. Glavin, G. B.: Selective noradrenaline depletion markedly alters stress responses in rats. Life Sci 37, 461-465 (1985)
77. Glavin, G. B.: Stress and brain noradrenaline: A review. Neurosci Biobehav. Rev 9, 233-243 (1985)
78. Gold, P. W., Charney, D. S.: Diseases of the mind and brain: Depression: A disease of the mind, brain, and body. Am. J. Psychiatry 159, 1826 (2002)
79. Gold, P. W., Chrousos, G. P.: Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol. Psychiatry 7, 254-275 (2002)
80. Gross, C. G.: Neurogenesis in the adult brain: Death of a dogma. Nat. Rev Neurosci 1, 67-73 (2000)
81. Gur, R. E., Keshavan, M. S., Lawrie, S. M.: Deconstructing psychosis with human brain imaging. Schizophr. Bull. 33, 921-931 (2007)
82. Halim, N. D., Weickert, C. S., McClintock, B. W., Weinberger, D. R., Lipska, B. K.: Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 29, 1063-1069 (2004)
83. Harrison, P. J., Weinberger, D. R.: Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 10, 40-68 (2005)
84. Heesen, C., Nawrath, L., Reich, C., Bauer, N., Schulz, K. H., Gold, S. M.: Fatigue in multiple sclerosis: An example of cytokine mediated sickness behaviour? J. Neurol. Neurosurg. Psychiatry 77, 34-39 (2006)
85. Heim, C., Newport, D. J., Heit, S., Graham, Y. P., Wilcox, M., Bonsall, R., Miller, A. H., Nemeroff, C. B.: Pituitary-Adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 284, 592-597 (2000)
86. Heim, C., Plotsky, P. M., Nemeroff, C. B.: Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology 29, 641-648 (2004)
87. Hillhouse, E. W., Milton, N. G.: Effect of acetylcholine and 5-hydroxytryptamine on the secretion of corticotrophin-releasing factor-41 and arginine vasopressin from the rat hypothalamus in vitro. J Endocrinol. 122, 713-718 (1989)
88. Holmes, P. V.: Rodent models of depression: Reexamining validity without anthropomorphic inference. Crit. Rev Neurobiol 15, 143-174 (2003)
89. Holsboer, F.: The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 33, 181-214 (1999)
90. Huang, Y. Y., Peng, C. H., Yang, Y. P., Wu, C. C., Hsu, W. M., Wang, H. J., Chan, K. H., Chou, Y. P., Chen, S. J., Chang, Y. L.: Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. J Pharmacol Sci 104, 61-72 (2007)
91. Huggett, J., Dheda, K., Bustin, S., Zumla, A.: Real-Time RT-PCR normalisation; strategies and considerations. Genes Immun. 6, 279-284 (2005)
92. Husum, H., Mikkelsen, J. D., Hogg, S., Mathe, A. A., Mork, A.: Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 39, 1463-1473 (2000)
93. Iga, J., Ueno, S., Yamauchi, K., Motoki, I., Tayoshi, S., Ohta, K., Song, H., Morita, K., Rokutan, K., Ohmori, T.: Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. 389, 12-16 (2005)
94. Iga, J., Ueno, S., Yamauchi, K., Numata, S., Motoki, I., Tayoshi, S., Kinouchi, S., Ohta, K., Song, H., Morita, K., Rokutan, K., Tanabe, H., Sano, A., Ohmori, T.: Gene expression and association analysis of LIM (PDLIM5) in major depression. Neurosci Lett. 400, 203-207 (2006)
95. Iga, J., Ueno, S., Yamauchi, K., Numata, S., Kinouchi, S., Tayoshi-Shibuya, S., Song, H., Ohmori, T.: Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 628-632 (2007)
96. Iga, J., Ueno, S., Yamauchi, K., Numata, S., Tayoshi-Shibuya, S., Kinouchi, S., Nakataki, M., Song, H., Hokoishi, K., Tanabe, H., Sano, A., Ohmori, T.: Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 658-663 (2007)
97. Insel, T. R., Scolnick, E. M.: Cure therapeutics and strategic prevention: Raising the bar for mental health research. Mol. Psychiatry 11, 11-17 (2006)
98. Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., Kunzel, H. E., Pfennig, A., Uhr, M., Holsboer, F.: Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-A potential biomarker? Biol. Psychiatry 62, 47-54 (2007)
99. Jarvinen, A. K., Hautaniemi, S., Edgren, H., Auvinen, P., Saarela, J., Kallioniemi, O. P., Monni, O.: Are data from different gene expression microarray platforms comparable? Genomics 83, 1164-1168 (2004)
100. Jin, P., Zhao, Y., Ngalame, Y., Panelli, M. C., Nagorsen, D., Monsurro, V., Smith, K., Hu, N., Su, H., Taylor, P. R., Marincola, F. M., Wang, E.: Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics 5, 55 (2004)
101. Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., Krishnan, K. R.: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 1-12 (2007)
102. Kalman, J., Palotas, A., Juhasz, A., Rimanoczy, A., Hugyecz, M., Kovacs, Z., Galsi, G., Szabo, Z., Pakaski, M., Feher, L. Z., Janka, Z., Puskas, L. G.: Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression-evolution of antidepressants and the role of the 'neuro-immune' system. Neurochem Res 30, 1429-1438 (2005)
103. Karson, C. N., Mrak, R. E., Schluterman, K. O., Sturner, W. Q., Sheng, J. G., Griffin, W. S.: Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: A possible neurochemical basis for 'hypofrontality'. Mol Psychiatry 4, 39-45 (1999)
104. Kasckow, J. W., Regmi, A., Sheriff, S., Mulchahey, J., Geracioti, T. D., Jr.: Regulation of corticotropin-releasing factor messenger RNA by nicotine in an immortalized amygdalar cell line. Life Sci 65, 2709-2714 (1999)
105. Kasckow, J. W., Aguilera, G., Mulchahey, J. J., Sheriff, S., Herman, J. P.: In vitro regulation of corticotropin-releasing hormone. Life Sci 73, 769-781 (2003)
106. Keck, M. E., Wigger, A., Welt, T., Muller, M. B., Gesing, A., Reul, J. M., Holsboer, F., Landgraf, R., Neumann, I. D.: Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-Anxious rats: Implications for pathogenesis of affective disorders. Neuropsychopharmacology 26, 94-105 (2002)
107. Keck, M. E., Welt, T., Muller, M. B., Uhr, M., Ohl, F., Wigger, A., Toschi, N., Holsboer, F., Landgraf, R.: Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 28, 235-243 (2003)
108. Khan, A., Schwartz, K., Kolts, R. L., Ridgway, D., Lineberry, C.: Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol. Psychiatry 62, 65-71 (2007)
109. Kitayama, N., Vaccarino, V., Kutner, M., Weiss, P., Bremner, J. D.: Magnetic resonance imaging (MRI) measurement of hippocampal volume in posttraumatic stress disorder: A meta-Analysis. J. Affect. Disord. 88, 79-86 (2005)
110. Kodama, M., Fujioka, T., Duman, R. S.: Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 56, 570-580 (2004)
111. Koldzic-Zivanovic, N., Seitz, P. K., Cunningham, K. A., Thomas, M. L., Hughes, T. K.: Serotonin regulation of serotonin uptake in RN46A cells. Cell Mol Neurobiol 26, 979-987 (2006)
112. Konradi, C.: Gene expression microarray studies in polygenic psychiatric disorders: Applications and data analysis. Brain Res Brain Res Rev 50, 142-155 (2005)
113. Koob, G. F.: Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 46, 1167-1180 (1999)
114. Kromer, S. A., Kessler, M. S., Milfay, D., Birg, I. N., Bunck, M., Czibere, L., Panhuysen, M., Putz, B., Deussing, J. M., Holsboer, F., Landgraf, R., Turck, C. W.: Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci 25, 4375-4384 (2005)
115. Kromer, S. A., Kessler, M. S., Milfay, D., Birg, I. N., Bunck, M., Czibere, L., Panhuysen, M., Putz, B., Deussing, J. M., Holsboer, F., Landgraf, R., Turck, C. W.: Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci 25, 4375-4384 (2005)
116. Kunzel, H. E., Binder, E. B., Nickel, T., Ising, M., Fuchs, B., Majer, M., Pfennig, A., Ernst, G., Kern, N., Schmid, D. A., Uhr, M., Holsboer, F., Modell, S.: Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-Adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology 28, 2169-2178 (2003)
117. Kupfer, D. J.: REM latency: A psychobiologic marker for primary depressive disease. Biol. Psychiatry 11, 159-174 (1976)
118. Kupfer, D. J.: Sleep research in depressive illness: Clinical implications-A tasting menu. Biol. Psychiatry 38, 391-403 (1995)
119. Kupfer, D. J., Targ, E., Stack, J.: Electroencephalographic sleep in unipolar depressive subtypes: Support for a biological and familial classification. J. Nerv. Ment. Dis. 170, 494-498 (1982)
120. Kupfer, D. J., Reynolds, C. F., III, Grochocinski, V. J., Ulrich, R. F., McEachran, A.: Aspects of short REM latency in affective states: A revisit. Psychiatry Res. 17, 49-59 (1986)
121. Kushwaha, N., Albert, P. R.: Coupling of 5-HT1A autoreceptors to inhibition of mitogen-Activated protein kinase activation via G beta gamma subunit signaling. Eur J Neurosci 21, 721-732 (2005)
122. Landgraf, R., Wigger, A.: High vs low anxiety-related behavior rats: An animal model of extremes in trait anxiety. Behav. Genet. 32, 301-314 (2002)
123. Landgraf, R., Wigger, A., Holsboer, F., Neumann, I. D.: Hyper-reactive hypothalamo-pituitary-Adrenocortical axis in rats bred for high anxiety-related behaviour. J. Neuroendocrinol. 11, 405-407 (1999)
124. Lauer, C. J., Riemann, D., Wiegand, M., Berger, M.: From early to late adulthood. Changes in EEG sleep of depressed patients and healthy volunteers. Biol. Psychiatry 29, 979-993 (1991)
125. Lehrmann, E., Hyde, T. M., Vawter, M. P., Becker, K. G., Kleinman, J. E., Freed, W. J.: The use of microarrays to characterize neuropsychiatric disorders: Postmortem studies of substance abuse and schizophrenia. Curr. Mol Med 3, 437-446 (2003)
126. Leonard, B. E.: The HPA and immune axes in stress: The involvement of the serotonergic system. Eur. Psychiatry 20 Suppl 3, S302-S306 (2005)
127. Liebsch, G., Linthorst, A. C., Neumann, I. D., Reul, J. M., Holsboer, F., Landgraf, R.: Behavioral, physiological, and neuroendocrine stress responses and differential sensitivity to diazepam in two Wistar rat lines selectively bred for high-And low-Anxiety-related behavior. Neuropsychopharmacology 19, 381-396 (1998)
128. Liebsch, G., Montkowski, A., Holsboer, F., Landgraf, R.: Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour. Behav Brain Res 94, 301-310 (1998)
129. Lima, L., Mata, S., Urbina, M.: Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression. Neuroimmunomodulation. 12, 299-306 (2005)
130. Lorrain, D. S., Baccei, C. S., Correa, L. D., Bristow, L. J.: Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stressevoked extracellular norepinephrine levels. Neuropharmacology 48, 927-935 (2005)
131. Lucki, I.: The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8, 523-532 (1997)
132. Luo, Z., Geschwind, D. H.: Microarray applications in neuroscience. Neurobiol Dis 8, 183-193 (2001)
133. Lyketsos, C. G., Olin, J.: Depression in Alzheimer's disease: Overview and treatment. Biol. Psychiatry 52, 243-252 (2002)
134. Macmaster, F. P., Mirza, Y., Szeszko, P. R., Kmiecik, L. E., Easter, P. C., Taormina, S. P., Lynch, M., Rose, M., Moore, G. J., Rosenberg, D. R.: Amygdala and Hippocampal Volumes in Familial Early Onset Major Depressive Disorder. Biol. Psychiatry (2007)
135. Maier, W., Zobel, A., Wagner, M.: Schizophrenia and bipolar disorder: Differences and overlaps. Curr. Opin. Psychiatry 19, 165-170 (2006)
136. Maino, K., Gruber, R., Riedel, M., Seitz, N., Schwarz, M., Muller, N.: T-And B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res. 152, 173-180 (2007)
137. Malberg, J. E., Duman, R. S.: Cell proliferation in adult hippocampus is decreased by inescapable stress: Reversal by fluoxetine treatment. Neuropsychopharmacology 28, 1562-1571 (2003)
138. Marcotte, E. R., Srivastava, L. K., Quirion, R.: CDNA microarray and proteomic approaches in the study of brain diseases: Focus on schizophrenia and Alzheimer's disease. Pharmacol Ther 100, 63-74 (2003)
139. Marsteller, D. A., Barbarich-Marsteller, N. C., Patel, V. D., Dewey, S. L.: Brain metabolic changes following 4-week citalopram infusion: Increased (18)FDG uptake and gamma-Amino butyric acid levels. Synapse 61, 877-881 (2007)
140. McDonald, C., Zanelli, J., Rabe-Hesketh, S., Ellison-Wright, I., Sham, P., Kalidindi, S., Murray, R. M., Kennedy, N.: Meta-Analysis of magnetic resonance imaging brain morphometry studies in bipolar disorder. Biol. Psychiatry 56, 411-417 (2004)
141. McEwen, B. S.: Plasticity of the hippocampus: Adaptation to chronic stress and allostatic load. Ann N Y Acad Sci 933, 265-277 (2001)
142. Middleton, F. A., Mirnics, K., Pierri, J. N., Lewis, D. A., Levitt, P.: Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22, 2718-2729 (2002)
143. Milak, M. S., Parsey, R. V., Keilp, J., Oquendo, M. A., Malone, K. M., Mann, J. J.: Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch. Gen. Psychiatry 62, 397-408 (2005)
144. Millan, M. J.: The neurobiology and control of anxious states. Prog. Neurobiol 70, 83-244 (2003)
145. Millan, M. J.: The role of monoamines in the actions of established and 'novel' antidepressant agents: A critical review. Eur J Pharmacol 500, 371-384 (2004)
146. Millan, M. J., Gobert, A., Bervoets, K., Rivet, J. M., Veiga, S., Brocco, M.: Induction of spontaneous tail-flicks in rats by blockade of transmission at N-methyl-D-Aspartate receptors: Roles of multiple monoaminergic receptors in relation to the actions of antipsychotic agents. J Pharmacol Exp Ther 292, 672-683 (2000)
147. Mir, K. U.: Ultrasensitive RNA profiling: Counting single molecules on microarrays. Genome. Res 16, 1195-1197 (2006)
148. Mirnics, K., Pevsner, J.: Progress in the use of microarray technology to study the neurobiology of disease. Nat. Neurosci 7, 434-439 (2004)
149. Mirnics, K., Levitt, P., Lewis, D. A.: Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry 60, 163-176 (2006)
150. Molina, V. A., Heyser, C. J., Spear, L. P.: Chronic variable stress enhances the stimulatory action of a low dose of morphine: Reversal by desipramine. Eur J Pharmacol 260, 57-64 (1994)
151. Morey, J. S., Ryan, J. C., Van Dolah, F. M.: Microarray validation: Factors influencing correlation between oligonucleotide microarrays and real-Time PCR. Biol Proced. Online. 8, 175-193 (2006)
152. Mortensen, O. V., Thomassen, M., Larsen, M. B., Whittemore, S. R., Wiborg, O.: Functional analysis of a novel human serotonin transporter gene promoter in immortalized raphe cells. Brain Res Mol Brain Res 68, 141-148 (1999)
153. Mulchahey, J. J., Regmi, A., Sheriff, S., Balasubramaniam, A., Kasckow, J. W.: Coordinate and divergent regulation of corticotropin-releasing factor (CRF) and CRF-binding protein expression in an immortalized amygdalar neuronal cell line. Endocrinology 140, 251-259 (1999)
154. Nemeroff, C. B., Bremner, J. D., Foa, E. B., Mayberg, H. S., North, C.
155. Nestler, E. J., Gould, E., Manji, H., Buncan, M., Duman, R. S., Greshenfeld, H. K., Hen, R., Koester, S., Lederhendler, I., Meaney, M., Robbins, T., Winsky, L., Zalcman, S.: Preclinical models: Status of basic research in depression. Biol Psychiatry 52, 503-528 (2002)
156. Newton, S. S., Collier, E. F., Hunsberger, J., Adams, D., Terwilliger, R., Selvanayagam, E., Duman, R. S.: Gene profile of electroconvulsive seizures: Induction of neurotrophic and angiogenic factors. J Neurosci 23, 10841-10851 (2003)
157. Newton, S. S., Duman, R. S.: Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS. Drugs 21, 715-725 (2007)
158. Nofzinger, E. A., Price, J. C., Meltzer, C. C., Buysse, D. J., Villemagne, V. L., Miewald, J. M., Sembrat, R. C., Steppe, D. A., Kupfer, D. J.: Towards a neurobiology of dysfunctional arousal in depression: The relationship between beta EEG power and regional cerebral glucose metabolism during NREM sleep. Psychiatry Res. 98, 71-91 (2000)
159. Ohmori, T., Morita, K., Saito, T., Ohta, M., Ueno, S., Rokutan, K.: Assessment of human stress and depression by DNA microarray analysis. J Med Invest. 52 Suppl, 266-271 (2005)
160. Owen, M. J., Craddock, N., O'donovan, M. C.: Schizophrenia: Genes at last? Trends Genet 21, 518-525 (2005)
161. Pariante, C. M., Dazzan, P., Danese, A., Morgan, K. D., Brudaglio, F., Morgan, C., Fearon, P., Orr, K., Hutchinson, G., Pantelis, C., Velakoulis, D., Jones, P. B., Leff, J., Murray, R. M.: Increased pituitary volume in antipsychotic-free and antipsychotic-Treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 30, 1923-1931 (2005)
162. Parker, G.: Classifying depression: Should paradigms lost be regained? Am. J. Psychiatry 157, 1195-1203 (2000)
163. Parker, G., Malhi, G., Mitchell, P., Wilhelm, K., Austin, M. P., Crawford, J., Hadzi-Pavlovic, D.: Progressing a spectrum model for defining non-melancholic depression. Acta Psychiatr. Scand. 111, 139-143 (2005)
164. Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., Mosolov, S. N., Neznanov, N. G., Reznik, A. M., Smulevich, A. B., Tochilov, V. A., Johnson, B. G., Monn, J. A., Schoepp, D. D.: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat. Med. (2007)
165. Peng, C. H., Chiou, S. H., Chen, S. J., Chou, Y. C., Ku, H. H., Cheng, C. K., Yen, C. J., Tsai, T. H., Chang, Y. L., Kao, C. L.: Neuroprotection by Imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the MAPK pathway. Eur Neuropsychopharmacol. (2007)
166. Petit-Demouliere, B., Chenu, F., Bourin, M.: Forced swimming test in mice: A review of antidepressant activity. Psychopharmacology. (Berl) 177, 245-255 (2005)
167. Phillips, M. L., Drevets, W. C., Rauch, S. L., Lane, R.: Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol. Psychiatry 54, 515-528 (2003)
168. Porsolt, R. D., Le, P. M., Jalfre, M.: Depression: A new animal model sensitive to antidepressant treatments. Nature 266, 730-732 (1977)
169. Porsolt, R. D., Chermat, R., Lenegre, A., Avril, I., Janvier, S., Steru, L.: Use of the automated tail suspension test for the primary screening of psychotropic agents. Arch. Int Pharmacodyn. Ther 288, 11-30 (1987)
170. Posternak, M. A., Zimmerman, M.: Partial validation of the atypical features subtype of major depressive disorder. Arch. Gen. Psychiatry 59, 70-76 (2002)
171. Pruessner, J. C., Champagne, F., Meaney, M. J., Dagher, A.: Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: A positron emission tomography study using [11C]raclopride. J. Neurosci. 24, 2825-2831 (2004)
172. Quitkin, F. M., Stewart, J. W., McGrath, P. J., Tricamo, E., Rabkin, J. G., Ocepek-Welikson, K., Nunes, E., Harrison, W., Klein, D. F.: Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br. J. Psychiatry Suppl 30-34 (1993)
173. Ramirez, B. M., Bostic, J. Q., Davies, D., Rush, A. J., Witte, B., Hendrickse, W., Barnett, V.: Methods to improve diagnostic accuracy in a community mental health setting. Am. J. Psychiatry 157, 1599-1605 (2000)
174. Rasmussen, K., Beitner-Johnson, D. B., Krystal, J. H., Aghajanian, G. K., Nestler, E. J.: Opiate withdrawal and the rat locus coeruleus: Behavioral, electrophysiological, and biochemical correlates. J Neurosci 10, 2308-2317 (1990)
175. Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., Kaye, J. A., Leszek, J., Miller, B. L., Minthon, L., Quinn, J. F., Rabinovici, G. D., Robinson, W. H., Sabbagh, M. N., So, Y. T., Sparks, D. L., Tabaton, M., Tinklenberg, J., Yesavage, J. A., Tibshirani, R., Wyss-Coray, T.: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med (2007)
176. Robert, J. J., Hoffmann, R. F., Emslie, G. J., Hughes, C., Rintelmann, J., Moore, J., Armitage, R.: Sex and age differences in sleep macroarchitecture in childhood and adolescent depression. Sleep 29, 351-358 (2006)
177. Rocc, P., De, L. C., Eva, C., Marchiaro, L., Milani, A. M., Musso, R., Ravizza, L., Zanalda, E., Bogetto, F.: Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Prog. Neuropsychopharmacol. Biol Psychiatry 26, 1155-1160 (2002)
178. Rokutan, K., Morita, K., Masuda, K., Tominaga, K., Shikishima, M., Teshima-Kondo, S., Omori, T., Sekiyama, A.: Gene expression profiling in peripheral blood leukocytes as a new approach for assessment of human stress response. J Med Invest. 52, 137-144 (2005)
179. Rokutan, K., Morita, K., Masuda, K., Tominaga, K., Shikishima, M., Teshima-Kondo, S., Omori, T., Sekiyama, A.: Gene expression profiling in peripheral blood leukocytes as a new approach for assessment of human stress response. J Med Invest. 52, 137-144 (2005)
180. Rozeboom, A. M., Akil, H., Seasholtz, A. F.: Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. Proc Natl Acad Sci U S A 104, 4688-4693 (2007)
181. Rush, A. J., Zimmerman, M., Wisniewski, S. R., Fava, M., Hollon, S. D., Warden, D., Biggs, M. M., Shores-Wilson, K., Shelton, R. C., Luther, J. F., Thomas, B., Trivedi, M. H.: Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. J. Affect. Disord. 87, 43-55 (2005)
182. Sahay, A., Hen, R.: Adult hippocampal neurogenesis in depression. Nat. Neurosci 10, 1110-1115 (2007)
183. Salchner, P., Singewald, N.: Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology 43, 1238-1248 (2002)
184. Salchner, P., Sartori, S. B., Sinner, C., Wigger, A., Frank, E., Landgraf, R., Singewald, N.: Airjet and FG-7142-induced Fos expression differs in rats selectively bred for high and low anxietyrelated behavior. Neuropharmacology 50, 1048-1058 (2006)
185. Schena, M., Shalon, D., Davis, R. W., Brown, P. O.: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470 (1995)
186. Schena, M., Shalon, D., Heller, R., Chai, A., Brown, P. O., Davis, R. W.: Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A 93, 10614-10619 (1996)
187. Scheuch, K., Lautenschlager, M., Grohmann, M., Stahlberg, S., Kirchheiner, J., Zill, P., Heinz, A., Walther, D. J., Priller, J.: Characterization of a Functional Promoter Polymorphism of the Human Tryptophan Hydroxylase 2 Gene in Serotonergic Raphe Neurons. Biol Psychiatry (2007)
188. Schmidt, H. D., Duman, R. S.: The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 18, 391-418 (2007)
189. Schratt, G. M., Tuebing, F., Nigh, E. A., Kane, C. G., Sabatini, M. E., Kiebler, M., Greenberg, M. E.: A brain-specific microRNA regulates dendritic spine development. Nature 439, 283-289 (2006)
190. Schulteis, G., Yackey, M., Risbrough, V., Koob, G. F.: Anxiogenic-like effects of spontaneous and naloxone-precipitated opiate withdrawal in the elevated plus-maze. Pharmacol Biochem Behav 60, 727-731 (1998)
191. Searfoss, G. H., Ryan, T. P., Jolly, R. A.: The role of transcriptome analysis in pre-clinical toxicology. Curr. Mol Med 5, 53-64 (2005)
192. Segman, R. H., Shefi, N., Goltser-Dubner, T., Friedman, N., Kaminski, N., Shalev, A. Y.: Peripheral blood mononuclear cell gene expression profiles identify emergent post-Traumatic stress disorder among trauma survivors. Mol. Psychiatry 10, 500-13, 425 (2005)
193. Selemon, L. D., Goldman-Rakic, P. S.: The reduced neuropil hypothesis: A circuit based model of schizophrenia. Biol Psychiatry 45, 17-25 (1999)
194. Seligman, M. E., Weiss, J., Weinraub, M., Schulman, A.: Coping behavior: Learned helplessness, physiological change and learned inactivity. Behav Res Ther 18, 459-512 (1980)
195. Sheline, Y. I., Barch, D. M., Donnelly, J. M., Ollinger, J. M., Snyder, A. Z., Mintun, M. A.: Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: An fMRI study. Biol. Psychiatry 50, 651-658 (2001)
196. Shelton, R. C., Liang, S., Liang, P., Chakrabarti, A., Manier, D. H., Sulser, F.: Differential expression of pentraxin 3 in fibroblasts from patients with major depression. Neuropsychopharmacology 29, 126-132 (2004)
197. Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de, L. F., Kawasaki, E. S., Lee, K. Y., Luo, Y., Sun, Y. A., Willey, J. C., Setterquist, R. A., Fischer, G. M., Tong, W., Dragan, Y. P., Dix, D. J., Frueh, F. W., Goodsaid, F. M., Herman, D., Jensen, R. V., Johnson, C. D., Lobenhofer, E. K., Puri, R. K., Schrf, U., Thierry-Mieg, J., Wang, C., Wilson, M., Wolber, P. K., Zhang, L., Amur, S., Bao, W., Barbacioru, C. C., Lucas, A. B., Bertholet, V., Boysen, C., Bromley, B., Brown, D., Brunner, A., Canales, R., Cao, X. M., Cebula, T. A., Chen, J. J., Cheng, J., Chu, T. M., Chudin, E., Corson, J.: The MicroArray Quality Control (MAQC) project shows inter-And intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161 (2006)
198. Sibille, E., Arango, V., Galfalvy, H. C., Pavlidis, P., Erraji-Benchekroun, L., Ellis, S. P., John, M. J.: Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacology 29, 351-361 (2004)
199. Smagin, G. N., Harris, R. B., Ryan, D. H.: Corticotropin-releasing factor receptor antagonist infused into the locus coeruleus attenuates immobilization stress-induced defensive withdrawal in rats. Neurosci Lett. 220, 167-170 (1996)
200. Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., Zohar, J., Mendlewicz, J.: Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study. J. Clin. Psychiatry 68, 1062-1070 (2007)
201. Sousa, N., Cerqueira, J. J., Almeida, O. F.: Corticosteroid receptors and neuroplasticity. Brain Res Rev (2007)
202. Stafford, P., Brun, M.: Three methods for optimization of cross-laboratory and cross-platform microarray expression data. Nucleic. Acids Res 35, e72 (2007)
203. Stahl, S. M., Woo, D. J., Mefford, I. N., Berger, P. A., Ciaranello, R. D.: Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. Am. J. Psychiatry 140, 26-30 (1983)
204. Stewart, J. W., McGrath, P. J., Quitkin, F. M., Rabkin, J. G., Harrison, W., Wager, S., Nunes, E., Ocepek-Welikson, K., Tricamo, E.: Chronic depression: Response to placebo, imipramine, and phenelzine. J. Clin. Psychopharmacol. 13, 391-396 (1993)
205. Sullivan, P. F., Fan, C., Perou, C. M.: Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 261-268 (2006)
206. Sun, W., Park, K. W., Choe, J., Rhyu, I. J., Kim, I. H., Park, S. K., Choi, B., Choi, S. H., Park, S. H., Kim, H.: Identification of novel electroconvulsive shock-induced and activity-dependent genes in the rat brain. Biochem Biophys. Res Commun. 327, 848-856 (2005)
207. Suri, C., Fung, B. P., Tischler, A. S., Chikaraishi, D. M.: Catecholaminergic cell lines from the brain and adrenal glands of tyrosine hydroxylase-SV40 T antigen transgenic mice. J Neurosci 13, 1280-1291 (1993)
208. Suzuki, Y., Sawamura, K., Someya, T.: Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 31, 825-831 (2006)
209. Swanson, C. J., Perry, K. W., Schoepp, D. D.: The mGlu2/3 receptor agonist, LY354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex. J Neurochem 88, 194-202 (2004)
210. Swanson, C. J., Blackburn, T. P., Zhang, X., Zheng, K., Xu, Z. Q., Hokfelt, T., Wolinsky, T. D., Konkel, M. J., Chen, H., Zhong, H., Walker, M. W., Craig, D. A., Gerald, C. P., Branchek, T. A.: Anxiolytic-And antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A 102, 17489-17494 (2005)
211. Swanson, C. J., Bures, M., Johnson, M. P., Linden, A. M., Monn, J. A., Schoepp, D. D.: Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev Drug Discov. 4, 131-144 (2005)
212. Tanna, V. L., Wilson, A. F., Winokur, G., Elston, R. C.: Linkage analysis of pure depressive disease. J Psychiatr. Res 23, 99-107 (1989)
213. Tanner, M. A., Berk, L. S., Felten, D. L., Blidy, A. D., Bit, S. L., Ruff, D. W.: Substantial changes in gene expression level due to the storage temperature and storage duration of human whole blood. Clin Lab. Haematol. 24, 337-341 (2002)
214. Taylor, D. J., Lichstein, K. L., Durrence, H. H., Reidel, B. W., Bush, A. J.: Epidemiology of insomnia, depression, and anxiety. Sleep 28, 1457-1464 (2005)
215. Taylor, M. A., Fink, M.: Restoring melancholia in the classification of mood disorders. J. Affect. Disord. (2007)
216. Thiel, G., Cibelli, G.: Corticotropin-releasing factor and vasoactive intestinal polypeptide activate gene transcription through the cAMP signaling pathway in a catecholaminergic immortalized neuron. Neurochem Int 34, 183-191 (1999)
217. Toro, C. T., Deakin, J. F.: Adult neurogenesis and schizophrenia: A window on abnormal early brain development? Schizophr. Res 90, 1-14 (2007)
218. Tsao, C. W., Lin, Y. S., Chen, C. C., Bai, C. H., Wu, S. R.: Cytokines and serotonin transporter in patients with major depression. Prog. Neuropsychopharmacol. Biol Psychiatry 30, 899-905 (2006)
219. Tsuang, M. T., Nossova, N., Yager, T., Tsuang, M. M., Guo, S. C., Shyu, K. G., Glatt, S. J., Liew, C. C.: Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: A preliminary report. Am. J Med Genet B Neuropsychiatr. Genet 133, 1-5 (2005)
220. Ungerstedt, U.: Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand. Suppl. 367, 1-48 (1971)
221. Vandergriff, J., Rasmussen, K.: The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 38, 217-222 (1999)
222. Vandesompele, J., De, P. K., Pattyn, F., Poppe, B., Van, R. N., De, P. A., Speleman, F.: Accurate normalization of real-Time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome. Biol 3, RESEARCH0034 (2002)
223. Van Praag, H. M.: On what evidence should education concerning depression be based? Int Clin Psychopharmacol. 14, Suppl 3, S35-S39 (1999)
224. Vawter, M. P., Ferran, E., Galke, B., Cooper, K., Bunney, W. E., Byerley, W.: Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr. Res 67, 41-52 (2004)
225. Vawter, M. P., Shannon, W. C., Ferran, E., Matsumoto, M., Overman, K., Hyde, T. M., Weinberger, D. R., Bunney, W. E., Kleinman, J. E.: Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia. Neurochem Res 29, 1245-1255 (2004)
226. Velculescu, V. E., Zhang, L., Vogelstein, B., Kinzler, K. W.: Serial analysis of gene expression. Science 270, 484-487 (1995)
227. Vermetten, E., Vythilingam, M., Southwick, S. M., Charney, D. S., Bremner, J. D.: Long-Term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol. Psychiatry 54, 693-702 (2003)
228. Vgontzas, A. N., Bixler, E. O., Chrousos, G. P.: Obesity-related sleepiness and fatigue: The role of the stress system and cytokines. Ann. N. Y. Acad. Sci. 1083, 329-344 (2006)
229. Vogel, M., Pfeifer, S., Schaub, R. T., Grabe, H. J., Barnow, S., Freyberger, H. J., Cascorbi, I.: Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 50, 305-310 (2004)
230. Wagner, J. A., Williams, S. A., Webster, C. J.: Biomarkers and surrogate end points for fit-forpurpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther. 81, 104-107 (2007)
231. Walker, E. F., Walder, D. J., Reynolds, F.: Developmental changes in cortisol secretion in normal and at-risk youth. Dev. Psychopathol. 13, 721-732 (2001)
232. Walsh, B. T., Seidman, S. N., Sysko, R., Gould, M.: Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 287, 1840-1847 (2002)
233. Walsh, J. K., Deacon, S., Dijk, D. J., Lundahl, J.: The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. Sleep 30, 593-602 (2007)
234. Wang, H. D., Dunnavant, F. D., Jarman, T., Deutch, A. Y.: Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 29, 1230-1238 (2004)
235. Wang, Y., Barbacioru, C., Hyland, F., Xiao, W., Hunkapiller, K. L., Blake, J., Chan, F., Gonzalez, C., Zhang, L., Samaha, R. R.: Large scale real-Time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 7, 59 (2006)
236. Warner-Schmidt, J. L., Duman, R. S.: VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci U S A 104, 4647-4652 (2007)
237. Weintraub, D., Stern, M. B.: Psychiatric complications in Parkinson disease. Am. J. Geriatr. Psychiatry 13, 844-851 (2005)
238. West, A. P.: Neurobehavioral studies of forced swimming: The role of learning and memory in the forced swim test. Prog. Neuropsychopharmacol. Biol Psychiatry 14, 863-877 (1990)
239. Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpe, S., Maes, M.: IDO and interferon-Alpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 10, 538-544 (2005)
240. Willner, P.: Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation. Psychopharmacology. (Berl) 134, 319-329 (1997)
241. Wong, D. L., Tank, A. W.: Stress-induced catecholaminergic function: Transcriptional and posttranscriptional control. Stress 10, 121-130 (2007)
242. Xu, J. F., Chen, X. Q., Du, J. Z., Wang, T. Y.: CRF receptor type 1 mediates continual hypoxiainduced CRF peptide and CRF mRNA expression increase in hypothalamic PVN of rats. Peptides. 26, 639-646 (2005)
243. Zetzsche, T., Frodl, T., Preuss, U. W., Schmitt, G., Seifert, D., Leinsinger, G., Born, C., Reiser, M., Moller, H. J., Meisenzahl, E. M.: Amygdala volume and depressive symptoms in patients with borderline personality disorder. Biol. Psychiatry 60, 302-310 (2006)
244. Zhu, C. B., Blakely, R. D., Hewlett, W. A.: The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-Alpha activate serotonin transporters. Neuropsychopharmacology 31, 2121-2131 (2006)
245. Zieker, J., Zieker, D., Jatzko, A., Dietzsch, J., Nieselt, K., Schmitt, A., Bertsch, T., Fassbender, K., Spanagel, R., Northoff, H., Gebicke-Haerter, P. J.: Differential gene expression in peripheral blood of patients suffering from post-Traumatic stress disorder. Mol Psychiatry 12, 116-118 (2007)
246. Zimmerman, M., Chelminski, I., Posternak, M. A.: Generalizability of antidepressant efficacy trials: Differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am. J. Psychiatry 162, 1370-1372 (2005)
247. Zusso, M., Debetto, P., Guidolin, D., Giusti, P.: Cerebellar granular cell cultures as an in vitro model for antidepressant drug-induced neurogenesis. Crit. Rev Neurobiol 16, 59-65 (2004)